[Differences in clinical and laboratory features and survival between Chinese and Western patients with myelodysplastic neoplasm].

<b>Objective:</b> To compare the clinical and laboratory characteristics and survival between Chinese and Western patients with myelodysplastic neoplasms (MDS) . <b>Methods:</b> Clinical and laboratory data were collected from 1,464 primary adult patients diagnosed with MDS at the Institute of Hematology & Blood Diseases Hospital from August 2016 to June 2024. Collected data were retrospectively analyzed and compared with 2,191 patients from the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) . <b>Results:</b> Chinese patients were significantly younger (median age: 56 years <i>vs</i>. 72 years, <i>P</i><0.001) and experienced more severe hematopenia (<i>P</i><0.001) compared with patients from the IWG-PM. Further, Chinese patients exhibited a higher percentage of isolated del (20q), +8, and complex karyotypes as well as a lower percentage of normal karyotypes, del (5q), and -Y (<i>P</i><0.001). Higher U2AF1, NRAS, and NPM1 mutation rates and lower ASXL1, SF3B1, and RUNX1 mutation rates were observed in Chinese patients than in participants from the IWG-PM (<i>P</i><0.05). No significant difference in overall survival (OS) was found between the two groups (median OS: 48 [95% <i>CI</i>: 40 - 56]months, <i>vs</i>. 45[95% <i>CI</i>: 40 - 49] months; <i>P</i>=0.449). Among participants aged ≤45 years, Chinese patients demonstrated more trisomy 8 (<i>P</i>=0.070) and U2AF1 mutation (<i>P</i><0.001) and higher 4-year OS rate compared with those from the IWG-PM (75.5% <i>vs</i>. 62.1%, <i>P</i>=0.001). Among participants aged ≥70 years, Chinese patients exhibited more complex karyotypes but fewer del (5q) as well as more NPM1 but less SF3B1 and TET2 compared with those from the IWG-PM (<i>P</i><0.05). Chinese patients demonstrated shorter survival (median OS: 20 [95% <i>CI</i>: 13 - 27] months <i>vs</i>. 37 [95% <i>CI</i>: 32 - 42] months, <i>P</i><0.001) . <b>Conclusion:</b> Chinese and Western MDS patients differ in age of onset, clinical features, and cytogenetic or molecular genetic abnormalities, with significant differences persisting in age-matched groups. Although the OS is similar, disparities exist in survival for younger and older patients between the two populations.